Advanced search
Publication Cover
mAbs Volume 3, 2011 - Issue 1
Submit an article Journal homepage
6,410
Views
217
CrossRef citations to date
0
Altmetric
Report

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

What have we learned?

Rong Deng Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USACorrespondence[email protected]
,
Suhasini Iyer Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USA
,
Frank-Peter Theil Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USA
,
Deborah L. Mortensen Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USA
,
Paul J. Fielder Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USA
&
Saileta Prabhu Department of Pharmacokinetic and Pharmacodynamic Sciences; Genentech, Inc.; South San Francisco, CA USA
Pages 61-66 | Received 13 Oct 2010, Accepted 30 Sep 2010, Published online: 01 Jan 2011

References

  • Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009; 157:907 - 921
  • West GB, Brown JH. The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol 2005; 208:1575 - 1592
  • Boxenbaum H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 1984; 15:1071 - 1121
  • International conference on harmonization (ICH) of technical requirments for registration of pharmaceuticals for human use: ICH Harmonized Tripartite Guideline S6 (R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals 2009 www.ich.org/LOB/media/MEDIA5784.pdf
  • Deng R, Mortensen D, Prabhu S, Jumbe N, Iyer S, Fielder P. Prediction of human pharmacokinetics for monoclonal antibody 2007; San Diego CA AAPS National Biotechnology Conference http://www.aapsj.org/abstracts/NBC_2007/NBC07-000591.PDF
  • Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 2009; 49:1382 - 1402
  • Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 2010; 31:253 - 263
  • Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973; 1:435 - 461
  • Mahmood I. Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 2009; 98:3850 - 3861
  • Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23:2534 - 2543
  • Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13:1551 - 1559
  • Tang H, Mayersohn M. Accuracy of allometrically predicted pharmacokinetic parameters in humans: role of species selection. Drug Metab Dispos 2005; 33:1288 - 1293
  • Mahmood I, Balian JD. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 1996; 26:887 - 895
  • Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci 2004; 93:177 - 185
  • Mahmood I. Role of fixed coefficients and exponents in the prediction of human drug clearance: how accurate are the predictions from one or two species?. J Pharm Sci 2009; 98:2472 - 2493
  • Duconge J, Fernandez-Sanchez E, Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?. Biopharm Drug Dispos 2004; 25:177 - 186
  • Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res 2007; 24:1910 - 1918
  • Kelley SK, Gelzleichter T, Xie D, Lee WP, Darbonne WC, Qureshi F, et al. Preclinical pharmacokinetics, pharmacodynamics and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006; 148:1116 - 1123
  • Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, et al. Preclinical pharmacokinetics, interspecies scaling and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999; 288:371 - 378
  • Vugmeyster Y, Szklut P, Tchistiakova L, Abraham W, Kasaian M, Xu X. Preclinical pharmacokinetics, interspecies scaling and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol 2008; 8:477 - 483
  • Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548 - 558
  • Cho CY, Shin BS, Jung JH, Kim DH, Lee KC, Han SY, et al. Pharmacokinetic scaling of bisphenol A by species-invariant time methods. Xenobiotica 2002; 32:925 - 934
  • Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10:1093 - 1095
  • Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:633 - 659
  • Tang H, Mayersohn M. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 2006; 95:1783 - 1799

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.